# A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

> **NCT04605926** · PHASE3 · WITHDRAWN · sponsor: **Biocon Limited**

## Conditions studied

- Coronavirus

## Interventions

- **BIOLOGICAL:** EQ001
- **BIOLOGICAL:** EQ001 Placebo

## Key facts

- **NCT ID:** NCT04605926
- **Lead sponsor:** Biocon Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-11
- **Primary completion:** 2021-04
- **Final completion:** 2021-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor has currently elected to withhold study initiation
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04605926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04605926, "A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT04605926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*